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ABSTRACT
QUANTITATION WITHOUT CALIBRATION: RESPONSE PROFILE AS AN INDICATOR
OF TARGET AMOUNT
Mrittika Debnath, M.S.
Department of Chemistry and Biochemistry
Northern Illinois University, 2018
Irina Nesterova, Director
Quantitative assessment of biomarkers is essential in numerous contexts from decisionmaking in clinical situations to food quality monitoring to the interpretation of life-science research
ﬁndings. However, appropriate quantitation techniques are not as widely addressed as detection
methods. One of the major challenges in biomarker’s quantitation is the need to have a calibration
for correlating a measured signal to a target amount. The step complicates the methodologies and
makes them less sustainable. In this work, we addressed the issue via a new strategy: relying on
the position of response proﬁle rather than absolute signal for assessment of a target nucleic acid’s
amount. To enable the capability, we developed a target-probe binding mechanism based on a
negative cooperativity effect. A proof-of-concept example demonstrated that the model is suitable
for quantitative analysis of nucleic acids over a wide concentration range. The general principles
of the platform will be applicable for a variety of biomarkers such as nucleic acids, proteins,
peptides, and others.
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CHAPTER 1
INTRODUCTION
1.1 Nucleic Acid as Biomarker
1.1.1 Biomarker
In general, biomarkers are traceable and characterized substances that are indicators of
biological morphology, processes, and function [1]. The area with increased attention to
biomarkers is medicine, where they are used to diagnose various phases of diseases, monitor
severities of diseases and responses to therapies, and as predictors of prognosis of patients and
likely responses to therapy. Thus, according to National Institutes of Health (NIH), biomarker is a
characteristic or a sign that is objectively measured and evaluated as an indicator of various states
ranging from normal biologic processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention [3]. The NIH’s National Cancer Institute (NCI) defines biomarker as a
biological molecule found in blood, other body fluids, or tissues whose detection indicates the
normal or abnormal state of body [4]. It can either be a substance, structure, or process that can
predict the incidence of any outcome or disease [1]. It can also be indicative of effects of
treatments, interventions, and even unintended environmental exposure such as to chemicals or
nutrients, and the responses may be functional and physiological, biochemical at the cellular level,
or a molecular interaction [5].
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Based on disease conditions and other states, biomarkers can be of wide varieties and can
be used for different purposes [2]. As for clinical purposes, diagnostic biomarkers would permit
diagnosis at different states and severities of disease, predict therapeutic response of patients and
optimize the drug doses, as well as be informative with regard to underlying pathological causative
pathways. For example, bladder tumor antigen (BTA) and nuclear matrix protein-22 (NMP-22)
are used to diagnose bladder cancers based on urine analysis [2]. Biomarkers can also be
instrumental to assess the nature and extent of human exposure and risk from environmental
toxicants by analyzing the effects of a chemical component within an organism. As for example,
aflatoxin-albumin adducts in serum are considered to be one of the most reliable biomarkers of
food-based exposure to food. Aflatoxin is a hepatocarcinogen produced by fungi [7].
To be clinically acceptable, the analytical methods for biomarkers analysis should be
specific, highly efficient, economical, easy to perform and reproducible by different technicians
across different laboratories [6]. Several well-established approaches for analyzing different
biomarkers exist. For example, quantitative PCR for nucleic acid, ELISA for protein etc [8]. Even
though different analytical techniques have been developed for detecting the biomarkers, their
quantitation is not as widely established as their detection. In this paper, we focused on nucleic
acid-based biomarkers and approaches for their quantitative analysis.
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1.1.2 Nucleic Acids
Nucleic acids are very important biomolecules that are essential for all forms of life. They
are composed of nucleotides (Figure 1.1. (a)) which are monomers made of three components: a 5carbon sugar, a phosphate group, and a nitrogenous or nucleobases base. Depending on their
composition, they come in two naturally occurring varieties: deoxyribonucleic acid (DNA) and
ribonucleic acid (RNA) [9].

(a)

(b)

Figure 1.1. Nucleic acids and their use as biomarker (a) DNA and RNA strands and their
nucleobases [10]; (b) Targets and applications for nucleic acid detection and quantitation assays.
Examples of detection targets and applications where fast, cost-effective nucleic acid analysis
could revolutionize medical diagnostics and treatments. These figures are reproduced by
permission from [11]. Copyright 2017, American Chemical Society.
DNA and RNA are essential for all living systems. DNA, mostly found in double helix
form, is the carrier of genetic information and encodes the amino acid sequences of proteins, while
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RNA, usually found in single stranded form, plays a vital role in coding, decoding, regulation,
and expression of genes [12].
Due to their biological importance, nucleic acids are considered to be important biomarkers
for biological studies and medical diagnostics. Besides, nucleic acids can be used as high-affinity
recognition molecules for ions, small molecules, and proteins and can also be coupled with organic
or inorganic materials for assembly and construction purposes [13]. In the last decade, methods
involving analysis of nucleic acid gradually started complementing and even replacing the culturebased methods and immunochemical assays in routine laboratories involved in microbiological
analysis of pathogenic bacteria [12]. Here we discuss some DNA and RNA based biomarkers and
their uses.
1.1.2.1 DNA Biomarkers
DNA is an important biological molecule mainly due to its role as a carrier of genetic
information. Certain genetic variations, or the sequence variations in DNA, make the molecule a
potential biomarker for various purposes. Single nucleotide polymorphisms (SNPs), short tandem
repeats (STRs), deletions, insertions, or other variation in the DNA sequence level are widely used
biomarkers in medicine, forensics, public health and other areas [14]. For example, DNA plays an
important role in clinical diagnosis in cancer and in profiling of mutations in oncogenes, tumor
suppressor in genes, and mismatch-repair genes. In these instances, DNA biomarkers can be
instrumental for cancer screening, classification, diagnosis, prognosis, and therapy monitoring in
medicine, forensics, public health, and other areas (Figure 1.1.) [15]. Besides, due to its ability to
recognize and hybridize complimentary sequences, DNA based biosensors are widely used for
sequence-specific analysis of nucleic acids. Thus, such analysis is very useful in detection and
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quantification of genetic variants such as modified organism, bacteria, and in other applications
[16]. The most common DNA biomarkers are discussed below:
1. Single nucleotide polymorphisms (SNP). Single nucleotide polymorphisms (SNPs) refer
to one of the most common variations that occur at a frequency of approximately 1 in 1000 base
pairs throughout the genome. These types of variations caused by the substitution of one single
nucleotide for another are believed to be stable and not deleterious to organisms (Figure 1.2.).
Some SNPs are able to influence promoter activity or DNA and pre-mRNA conformation. SNPs
can also play a direct or indirect role in phenotypic expression. Since some SNPs are functional,
these genetic variations are one of the factors associated with susceptibility to many common
diseases [17].

Figure 1.2. Single nucleotide polymorphism with alleles C and T. This figure is reproduced by
permission from [19]. Copyright 2013, ACM.
For example, DNAs with certain SNPs are biomarkers for different types of cancers like
XRCC1, ATM, p53 (lung, head, and neck cancers), CYP1A1, RAD1, BRCA1, BRCA2 (breast
cancer), and PGS2 (lung cancer) [18].
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2. Cell-free Circulating DNA and tumor DNA. Fragmented DNA that are found in
circulation in the cell-free component of body fluids like serum and plasma are known as
circulating cell-free DNA (cfDNA). The clinical utility of these circulating cell-free DNA has been
reported as an area of active research in many disciplines of medicine. For example, analysis of
fetal DNA can detect germline fetal changes weeks after conception, increased level of cfDNA
has been detected during exercise, end-stage renal failure, stroke, myocardial infarction, surgery,
and trauma etc [20].

Figure 1.3. Circulating cell-free nucleic acids. Genetic alterations are detectable in circulating
cell-free tumor DNA. Tumor cells release small fragments of cell-free DNA into circulation. The
fragments can be detected in blood or plasma and can be utilized as diagnostic or prognostic
biomarker. This figure is reproduced by permission from [20]. Copyright 2014, Journal of
Clinical Oncology, American Society of Clinical Oncology publisher.
In oncology, detection of cfDNA derived from tumors through liquid biopsy, also known
as circulating tumor DNA (ctDNA), gives a good opportunity for cancer management [21]. It
carries tumor-specific sequence alterations that are responsible for the initiation and progression
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of human cancers (Figure 1.3.) [24]. For example, tumor-specific DNA methylations can be
observed within ctDNAs [23]. Along with giving access to the tumor in noninvasive ways, the
detectable ctDNA from the patient can also be correlated with the stage of cancer in patient through
analysis at advanced and early stage. As for example, ctDNA was detectable in more than 75% of
patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast,
melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal,
prostate, or thyroid cancers [22].
In conclusion, cell-free DNA is an important biomarker for diagnosis, prognosis, and
guidance for treatment.
3. Genetically modified organisms. According to World Health Organization (WHO), the
organisms in which the genetic material has been altered in a way that does not occur naturally are
known as Genetically Modified Organism (GMO) [25]. Here, the genome has been engineered in
the laboratory to favor the expression of desired physiological traits or the production of desired
biological products like plants and animals. The most common approach for genetic engineering
is recombinant DNA technology. It involves the insertion of one or more individual genes or DNA
(donor) from an organism of one species into the DNA (deoxyribonucleic acid) of another
(plasmid DNA or vector DNA) (Figure 1.4.) and is passed to the progeny as a new component of
the

genome.

This

whole-genome

replacement,

involving

the

transplantation

of

one bacterial genome into the “cell body,” or cytoplasm, of another microorganism, results in
organism carrying the transgene is called a transgenic organism or a genetically modified
organism (GMO) [26].
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Figure 1.4. Steps involved in the engineering of a recombinant DNA molecule. The DNA of
interest are inserted in a plasmid or vector DNA and this newly produced recombinant DNAs are
introduced in bacterial cell for cell division to produce their clones. This figure is reproduced by
permission from [128]. Copyright 2018, Encyclopædia Britannica.

The global area of GMO crops increased to 90 million hectares in 2005 [25]. However, in
the European Union (EU) and also worldwide, public opinion has exhibited concern against
genetically modified crops (GMC) because of possible food safety and environmental issues [27].
Hence, due to low public acceptance, a clear labeling of the food products containing GM
component have been implemented to choose the food the consumers feel comfortable with [27].
The threshold level of the presence of genetically modified components within food is set at 1%;
below this level, labeling is not required [26].
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To label the food, a variety of GMO testing methods have been developed to detect and
quantify the biomolecules present in GMO but not present in their non-GM counterparts. For
European regulatory compliance, these methods are mainly based on the detecting recombinant
DNA, preferably ubiquitous but GMO-specific sequences such as P35S (35S Promoter originating
from Cauliflower Mosaic Virus (CaMV), T-nos (Nopaline Synthase Terminator originating from
Agrobacterium tumefaciens), or nptII (Neomycine Phosphotransferase gene) [28].
4. Copy number variations. Copy number variation (CNV) is a type of genetic variation in
sub microscopic level that contributes to phenotypic variance. It is defined as a DNA segment that
is 1 kb or larger and present at variable copy number in comparison with a reference genome.
Although the reason behind the variations in copy numbers is not very clear yet, studies have
shown that deletions, duplications, segmental duplications, insertions, inversions, and
translocations of chromosomal segments represent some of the processes resulting in CNV (Figure
1.5.) [30]. Those are widespread in human genomes and represent a significant source of genetic
variation.
With the aid of high resolution genome-wide technologies, over 38,000 CNVs (>100 bp in
size) and many other structural variations (structural variations, including balanced inversions and
translocations) have been identified in recent years [29]. Around 12% of the genome are now
subjected to copy number variation [31]. Changes in copy number might change the expression
levels of genes, evolving new or modified functions or expression patterns than those that can be
achieved by transcription of a single copy per genome and sometimes causes genetic imbalance
that leads to a group of pathological conditions known as genomic disorders. CNVs form at a faster
rate than other types of mutation and seem to do so by similar mechanisms in bacteria, yeast, and
humans. Hence, CNVs are a major source of variation among individual humans, human evolution
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and many diseases, including mental illness and developmental disorders [31]. For example, CNV
in terms of gain of the copies of SNCA gene are found to be linked to autosomal dominant
Parkinson’s disease [30].

Figure 1.5. Types of genomic variants. Genomic variants in form of CNVs can be classified
primarily as deletion, duplication, segmental duplication and inversion. These can encompass the
entire gene or a segment of a particular gene represented in the figure, reproduced by permission
from [30]. Copyright 2011, Springer Nature.

CNVs are also involved in cancer formation and progression and contribute to cancer
proneness [31]. For example, in a study, it showed that individuals who had four copies of g.CNV30450 located in Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2)
promoter, had an increased cancer risk (odds ratio = 1.94, 95% confidence interval [CI] = 1.61–
2.35) and a worse prognosis for individuals with lung cancer (with a median survival time of only
9 months) (hazard ratio = 1.47, 95% CI = 1.22–1.78) compared to those with two or three copies
(with a median survival time of 14 months). Four copies of g.CNV-30450 have also significantly
increased MAPKAPK2 expression, both in vitro and in vivo, compared with two or three copies
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[32]. It can be concluded that copy-number variation of functional gene can be used as a potential
biomarker for susceptibility to and prognosis for disease.
1.1.2.2 RNA Biomarkers
Due to a wide range of biological functions, RNA is an important biomarker. In a living
system, it serves as transmitters of genetic information for transcriptional and post-transcriptional
regulation of levels of protein. RNA biomarkers provide dynamic insights into cellular states and
regulatory processes. Potential RNA biomarkers are microRNA (miRNA), messenger RNA
(mRNA), ribosomal RNA (rRNA) etc. Major RNA biomarkers are discussed below.
1. Gene expression and mRNA. Gene expression is the process by which the genes encoded in
DNA is used to synthesize a functional gene product like protein through transcription (DNA to
mRNA) and translation (mRNA to protein) steps. It is the most fundamental level at which
the genotype gives rise to the phenotype, i.e., observable trait. Controlling which genes are
expressed enables the cell to control this phenotype like organisms’ shape, or act as enzymes
catalyzing specific metabolic pathways [40].
Gene expression profiling of candidate genes can provide mechanistic insights regarding
cellular activity. Expression pattern of a specific gene can be used as a diagnostic tool. For
example, increased expression of several genes in samples collected from patients of Inflammatory
Breast Cancer, is associated with phenotype, possibly related to increased metabolism and cell
proliferation. Gene expression profiling can also be used to determine if a bacterium is resistant to
antibiotic. For example, expression of bla1 gene in Bacillus anthracis strain is the major
contributor to high-level resistance to ampicillin antibiotic [42].
Ideally, measurement of expression or gene expression profiling is done by detecting and
measuring mRNA, showing the pattern of genes expressed by a cell at the transcription level.

12
However, some researchers measure the level of final gene product, like protein, as gene
expression measuring tool [33].
mRNA is a protein coding RNA molecule that convey the information of the amino acid
sequences of protein product from DNA to ribosome through transcription and translation [33]. It
is a good candidate as a biomarker as differential expression of protein coded genes in mRNA
would positively correlate with disease pathology. For example, expression panel of mRNA,
related to cell cycle progression, was used as prognosis marker to predict metastasis, recurrence,
and risk of prostate cancer [34].
Primary transcripts mRNA or pre-mRNA, transcribed in to mature mRNA by RNA
polymerase, are being developed as molecular biomarkers for the diagnosis and treatment of a
number of diseases. They can predict disease early and accurately for diagnostic and prognostic
purposes, as well as to identify individuals at risk (Figure 1.6.) [35]. For example, oral cancer
patients had significantly higher salivary IL-8 mRNA concentration than control subjects [36].
Blood mRNA biomarkers for individualized disease prediction and diagnosis are an exciting area
in medicine as blood mRNA shares more than 80% of the transcriptome with major tissues. In a
study, mRNA expression of nine genes in peripheral blood of patients suffering from Chronic
fatigue syndrome (CFS) has been established. And it was found that expression levels of mRNA
of those nine genes were changed significantly in CFS patients compared to healthy controls [37].
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Figure 1.6. Gene expression profiling. Differential Expression of Messenger RNA (mRNA) by
Myocyte and Lymphocyte (Panel A) and Gene-Expression Profiling Using DNA Microarrays
(Panel B). This figure is reproduced by permission from [38]. Copyright 2003, Massachusetts
Medical Society.

2. Micro RNAs (miRNAs). Micro RNAs (miRNAs) are small non-coding RNA molecules
of approximately 22 nucleotides. These are produced from transcripts that form stem-loop
structures. These are processed in the nucleus by a complex comprised of the RNase III enzyme
Drosha and a protein called Pasha in Drosophila or DGCR8 in mammals. Final processing is done
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by RNase III endonuclease Dicer complex. It appears to incorporate miRNA into the RNA-induced
silencing complex (RISC), which is the effector of RNAi (RNA interference) [44].
Controlling mRNA degradation and translation are important parts of gene expression
regulation. And these two important parts of gene expression are modulated by miRNA. As the
mature miRNAs are processed from long transcripts and are incorporated into the RISC complex,
it regulates gene expression by guiding the RISC complex toward specific target mRNAs. In many
studies it has been found that miRNAs can silence cytoplasmic mRNAs either by triggering an
endonuclease cleavage, by promoting translation repression, or possibly by accelerating mRNA
decapping. The exact mode of action of the RISC complex is still a matter of debate [44].
miRNAs have shown promise as candidate biomarkers. Abnormal expression levels of
miRNAs can affect the regulation of many cellular functions and gene network which can be
correlated with disease status and health. A recent study has demonstrated that differential
expression of miR-1, miR-133, miR-21, and miR-208 can contribute to various cardiac pathologies
like ischemic heart disease, arrhythmia, and cardiomyopathy. miR-155 plays an important role in
regulating blood pressure as it suppresses the expression of angiotensin II type-1 receptor. Also,
over-expression of miR 17-92 cluster can lead to several types of immune complex-mediated renal
diseases [45].
In addition, as 50% of human miRNAs are localized in fragile chromosomal regions, due
to DNA amplifications, deletions, or translocations during tumor development, their expression is
frequently deregulated in cancer [39]. For example, miR-15a and miR-16-1 expression is inversely
correlated (oncogenes and tumor suppressors) to B cell lymphoma2 (Bcl2) expression in chronic
lymphocytic leukemia (CLL). These are natural antisense Bcl2 interactors and both microRNAs
can negatively regulate Bcl2 at a posttranscriptional level. Hence, these could be used for therapy
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of Bcl2-overexpressing tumors (Figure 1.7.) [46]. The decreased expression of miR-Let-7 (highly
conserved miR) has been observed in number of cancers such as pulmonary, ovarian, gastric, and
skin. Also, miR-221 and miR-222 have been shown to be dysregulated in glioblastomas, liver and
ovarian cancers [45].

Figure 1.7. miRNAs as oncogenes and tumor suppressors. A tumor suppressor miRNA can have,
in fact, oncogene-like effects if the main targets for that specific cell types are oncogenes. An
oncogene miRNA can have, in fact, tumor suppressor-like effects if the main targets for that
specific cell types are tumor suppressors. The same miRNA, but in a different cell type, can have
as main target an oncogene, and therefore its overexpression will decrease the levels of the
oncogenic protein, practically protecting the cell from malignant transformation. The miRNA
genes are shown in blue, and their corresponding promoters are shown in orange. This figure is
reproduced by permission from [46]. Copyright 2005, National Academy of Sciences.

A derivative of miRNA, known as IsomiRs, with different genomic sequence formed by
alternative processing and modification (i.e. addition of nucleotide in 3’ end of sequence) of
predominant miRNA can also serve as a potential biomarker. Their changes in the relative
distribution can serve as a marker at different developmental and disease states. For example, some
IsomiRs preferentially are found in benign gastric tissue, whereas other IsomiRs are available in
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gastric tumors [47]. These studies have paved the way for the surge of activity to identify miRs
that could potentially serve as a biomarker.
3. Circulating cfRNA. Besides cell-free circulating DNA, circulating cell-free RNA can
serve as a biomarker since circulating gene transcripts have been detectable in the serum and
plasma of cancer patients (Figure 1.8.) [48]. While the tumor starts developing, the apoptotic and
necrotic cell deaths along with active cell secretion causes the release of circulating DNA, mRNA
(messenger RNA), and microRNA into the blood circulation. Since these circulating cell-free
RNAs show a similar genomic sequence like the primary tumor and even micrometastatic cells,
they serve as excellent blood biomarkers for cancer proliferation [39].
Some circulating mRNAs remain stable in the blood and plasma fluid from degradation
due to exosomes, such as microparticles, microvesicles or multivesicles [39]. Patients with high
level of CCND1 mRNA (encoding cyclin D1) are identified as poor overall survival in goodprognosis groups and non-responsive to tamoxifen who are suffering from breast cancer [39].

Figure 1.8. Sources of circulating cell-free nucleic acids in blood. Cell-free DNA and RNA enter
in blood flow from neoplastic colon cells. This figure is reproduced by permission from [49].
Copyright 2016, Taylor & Francis.
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The change in levels of cell-free miRNAs in serum is suggestive of a disease state as well. For
example, miR-134, miR-146, miR-221, miR-222 and miR-23a are found to be highly dysregulated
in serum of both lung and colorectal cancer patients [39].
4. rRNA. Ribosomal RNA is the major structural component of the ribosome and the most
abundant and universal noncoding RNAs in living organisms (except viruses) [50]. Small subunit
ribosomal RNA (SS rRNA; i.e. 16S and 18S rRNA) or the corresponding genes have become an
established biomarker to describe the phylogenetic diversity of microbial communities (Figure
1.9.). Due to its fast-degradable property, SS rRNA extracted from a sample can be assumed to be
derived from the currently active population. Its availability both in conserved and variable regions
allows it to design capture probes at various levels of phylogenetic evaluations. The advantage of
using rRNA is the availability of huge databases for comparative sequence analysis [51]. Recently,
it has been observed that the presence of Dehalococcoides16S rRNA gene sequences qualitatively
correlates with the generation of ethene from chlorinated ethenes, while the absence
of Dehalococcoides at sites correlates with the accumulation of cis-1,2-dichloroethene (cDCE)
[52]. However, the rRNA sequences generally provide few direct clues regarding the interactions
and metabolic capabilities of the microorganisms that these sequences represent [53].
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Figure 1.9. 16S r RNA detection in microbacteria collected from human skin. DNA isolated from
human skin is amplified using appropriate 16S rRNA primers and then subjected to sequencing
and subsequent processing. The sequences can then be alligned and phylogenetic analysis
performed to study evolutionary relationships. This figure is reproduced by permission from
[48]. Copyright 2011, Elsevier Ltd.

In conclusion, it can be said that nucleic acids are indispensable biomarkers for assessing a
variety of conditions ranging from routine food quality monitoring to clinical diagnostics to life
science research
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Some information on these biomarkers is summarized in Table 1.1

Table 1.1. Information of some common Biomarkers
Biomarker
SNP in DNA

Where it is present
DNA sequence
Blood and other
body fluid, tumor
cell

Values as biomarker
1 occurs every 1000 nucleotides

References
[54]

>118 ng/mL in cancer patient

[55]

GMO

recombinant DNA

>0.9% of the food

[56]

Copy number
variations in
DNA

DNA

6% to 19% of the human genome

[57]

158.6 ng/mL from lung cancer
patient

[58]

70% accuracy with .70 ROC
(receiver operating characteristics)

[59]

circulating
tumor DNA

Circulating
miRNA
gene expression
of RNA

Blood and other
body fluid, tumor
cell
specific code in
DNA

1.2 Approaches for quantitative analysis of nucleic acids
After reviewing some important nucleic acid biomarkers, it is obvious that accurate
information on these biomolecules is a valuable asset in a variety of situations. In those contexts,
not only qualitative but also quantitative information on speciﬁc oligonucleotides has a practical
signiﬁcance: As for example, the level of hepatitis B virus (HBV) DNA in serum reflects the
replicative activity of HBV [60]. Plasma miR-221 could be a useful biomarker for Pancreatic
cancer (PCa) detection, monitoring tumor dynamics and predicting malignant outcomes in PCa
patients as the Plasma miR-221 concentrations were significantly higher in PCa patients than that
in benign pancreatic tumors (P value =0.016) and controls (P value <0.0005) [61]. Hence,
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concentrations of speciﬁc DNA/RNAs are important clinical indicators [62]. Quantitative
information on certain pathogen genotypes like Crytosporidium, Naegleria fowleri, Giardia, and
the bacteria Salmonella typhimurium, Vibrio cholerae, Legionella, Escherichia coli O157:H7
Campylobacter jejuni etc. is essential for public health risk assessment [63-65]. Accurate
quantitation of genetically modiﬁed organisms is a subject of legislative regulations as well [27].
A number of various techniques for detection of nucleic acids has been established over
the recent decades [62]. However, quantitation of the same remain much more challenging and are
much less frequently addressed [66]. Here, some most common quantitative approaches for
quantitative analysis of nucleic acids are discussed.

1.2.1 Quantitative Polymerase Chain Reaction (qPCR)
One of the most commonly used methods for quantitative analysis of target nucleic acid
sequence is quantitative PCR. It is considered the gold standard method for sensitive, specific, and
quantitative detection of nucleic acids. Some of the most prominent examples include HIV-1 viral
load testing, detection of bacterial pathogens, and screening for many other organisms [67]. The
amplification reaction is performed by temperature cycling. High temperature (92-96℃) is applied
to denature (melt) the strands of the double helical DNA, known as template. Then temperature is
lowered (45-55℃) to let two single stranded short pieces of DNA or primers anneal to the template
for initiating the synthesis of the template copies. And finally, the temperature is set around 72º C,
which is optimum for the polymerase enzyme (Taq Polymerase) that extends the primers by
incorporating the dNTPs [62].
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qPCR is based on monitoring of product formation during amplification step. That’s why
it is also known as real-time PCR. Usually, a fluorescent reporter that bind product and increase
or change emission pattern upon binding are used (Figure 1.10.). A number of various probes and
dyes have been developed to be used as reporter [68]. In dye-based PCR, an intercalating dye
(typically SYBR green) is used. As PCR progresses, the emission of SYBR green increases with
the amount of double stranded product formed. Since, most of the cases, these dyes are sequence
non-specific reporters, the dyes are excellent for quantitative real-time PCR when samples are
compared at the same level of fluorescence in absence of interfering product DNA like nonspecific
products, primer dimers, or other amplification artifacts etc [68].

Figure 1.10. Fluorescent dye-based method. Here, the fluorophore emits light as it is in excitation
state during extension step in PCR cycle after binding with the newly formed double stranded
DNA. This figure is reproduced by permission from [69]. Copyright 2017, BitesizeBio.com.
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The disadvantage of this dye-based method is that it allows only one target examination at
a time and the dye will bind to any ds-DNA present in the sample whether they are specific
products or not [70, 71]. These labelled probes are based on nucleic acids or some of their synthetic
analogues such as the peptide nucleic acids (PNA) and the locked nucleic acids (LNA) [68]. In
LNA, the ribose moiety in sugar-phosphate backbone is structurally constrained by a methylene
bridge between the 2’-oxygen and the 4’-carbon atoms where the link ‘locks’ the sugar ring in the
fixed 3’ -endo conformation and form hybrids with complementary DNA or RNA sequences. In
PNA, the backbone composition is radically different (repeating N-(2-aminoethyl)-glycine units
linked by peptide bonds), however, they are structurally homomorphous to nucleic acids. PNA
provides a wider range of hybridization conditions and has an exceptional ability to capture duplex
DNA. Both of these synthetic nucleic acids have high binding affinity [74].
In probe-based qPCR, labelled probes are used where the dye labels are of two kinds: (i)
fluorophores with intrinsically strong fluorescence, such as fluorescein and rhodamine derivatives
that are brought into contact with a quencher molecule through structural conformation switch and
(ii) fluorophores that change their fluorescence properties upon binding nucleic acids [68]. Some
examples of probes with two fluorophores are the hydrolysis probes, popularly called Taqman
probes, Molecular Beacons, Hybridization probes and the Lion probes (Figure 1.11.) [72, 73] [75,
76]. Fluorophores usually form a donor–acceptor pair, where the donor dye is excited and transfers
its energy to the acceptor when the probe conformation is such that donor and acceptor are in close
proximity. The labels can interact either via FRET (Fluorescence Resonance Energy Transfer; both
donor and acceptor are fluorescent) or via RET (donor is fluorescent, and acceptor is a quencher)
[77].
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Figure 1.11. Mechanisms of some reporters used in real-time PCR: (A) the molecular beacon,
(B) the Taqman probe, (C) the hybridization probes, (D) the LightUp probe, (E) the simple
probe, (F) scorpion primer, (G) sequence non-specific dyes (SYBR Green/BOXTO). This figure
is reproduced by permission from [68]. Copyright 2006, Elsevier Ltd.

Thus, the fluorescence signal from a probe-based qPCR reaction is proportional to the
amount of the probe target sequence present in the sample. Probe-based qPCR is more specific
than intercalating dye-based qPCR as fluorescence in this method is the direct result of the
hybridization of two independent probes. It is often the technology used in qPCR diagnostic assays
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[70]. Another great advantage of using probes is for multiplexing, where several products are
amplified in the same tube and detected in parallel [68].
The quantitative capability of qPCR is based on monitoring the increased double stranded
product. During the initial cycles, the fluorescence signal is weak and cannot be distinguished from
the background. As the amount of product accumulates, a signal develops that initially increases
exponentially. This exponential amplification apparently allows quantitation of very small amount
of template. At a certain point, the fluorescence originating from the product accumulation
increases and can be distinguished from the background. This threshold is within the exponential
region of the amplification curve above the base line. The cycle number where the amplification
product crosses that detection threshold is the Quantification Cycle (CT) (Figure 1.12. (a)) [67].

(a)

(b)

Figure 1.12. qPCR response curves. (a) A threshold level is set sufficiently above background
and the number of cycles required to reach threshold, CT; (b) Response curves shown in
logarithmic scale. In the inset the CT values are plotted vs. the logarithm of the initial number of
template copies in the standard samples. These figures are reproduced by permission from [68].
Copyright 2006, Elsevier Ltd.
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Using this CT value, the quantity of unknown target can be obtained from a calibration curve
established by known standard target (Figure 1.12. (b)) [62].
In order to carry out a gene expression measurement (mRNA levels) in qPCR, an additional
reverse transcription (RT) step is required. RT-qPCR can be carried out in two-step or one-step
reaction (Figure 1.13.). In two-step reaction, the RNA is first reverse transcribed into cDNA using
oligo-dT primers, random oligomers, or gene-specific primers. An aliquot of this reversetranscription reaction is then added to the qPCR. In one-step RT-qPCR, both reverse transcription
and qPCR take place in the same tube, with reverse transcription preceding PCR. The second
method enables rapid processing of multiple samples and is easy to automate [70] [78, 79].

Figure 1.13. Basic steps of one and two step of RT- qPCR. In one step RT-qPCR, all elements
for PCR and cDNA are added in the same tube, in two step RT-qPCR, RNA is reverse
transcribed in cDNA and then the aliquot is transferred to a second tube along with other
elements of PCR. This figure is reproduced by permission from [80]. Copyright 2010, QIAGEN.

Although RT-qPCR is widely used to quantitate biologically relevant changes in mRNA
levels, a number of major concerns like the inherent variability of RNA, variability of extraction
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protocols, different reverse transcription and PCR efficiencies etc. are associated with this method.
As a consequence, it is important that an accurate method is chosen to control these variables [81].
Many methods are used to control some of these variables, for example normalization against the
total cell number, mass of the input material or RNA mass quantity. Since, exogenously added
mRNA or spikes can be used for standardization before RNA extraction, normalization against
these internal control genes is most frequently used as it can control all variables [82, 83]. Those
internal control genes are referred as housekeeping genes. Usually these housekeeping genes are
used as reference genes since they are expressed at a constant level in certain tissues, at all stages
of development and are unaffected by the experimental treatment. In order to normalize the
absolute quantification according to a single reference gene, a second set of kinetic PCR reactions
has to be performed for the invariant endogenous control (expressed reference gene) on all
experimental samples. However, many studies have shown that although some reference genes,
occasionally constant in a given cell type or experimental condition - can vary considerably. For
example, in one study, G3PDH and 18S rRNA were used as reference genes for total RNAs,
extracted from the cerebellum, brain cortex, brain stem and subcortical structures of different types
of rats. The G3PDH/18S rRNA ratios did not significantly vary among the samples, whereas in
another study, L32 and G3PDH transcripts, used as internal standards, showed higher variations
after adding activators in the culture medium. Also, without validating, the reference gene may
also show variations. These issues limited the options of using reference gene for variety of
conditions [82-84].
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1.2.2 Florescence In-Situ Hybridization
In-situ hybridization is a molecular cytogenic method that allows researchers to locate the
positions of specific nucleic acid sequences like genomic DNA, rRNA, mRNA etc. inside a cell or
tissue. It is performed by using a labeled DNA or RNA sequence as a probe which can identify or
quantify the naturally occurring counterpart of the sequence in a biological sample based on
molecular hybridization method. In order to visualize this binding event, as a signal transduction
platform, fluorescence labelled probes are now widely used. In this case, the approach is known
as fluorescence in-situ hybridization (FISH) [88].
FISH has provided significant advances in both research and diagnosis of hematological
malignancies and solid tumors. It can be applied for detecting genetic abnormalities such as
characteristic gene fusions, aneuploidy, loss of a chromosomal region or a whole chromosome or
to monitor the progression of an aberration serving as a technique that can help in both the
diagnosis of a genetic disease or suggesting prognostic outcomes. It can also be applied to such
research applications as gene mapping or the identification of novel oncogenes or genetic
aberrations that contribute towards various cancers [89].
In order to carry out FISH measurements, it is necessary to make either a fluorescent copy of
the probe sequence or a modified copy of the probe sequence that can be rendered fluorescent [88].
Fluorophores can be associated with nucleic acid probes by ‘direct labelling’ where fluorophores
are directly chemically conjugated with probes or by ‘indirect labelling’ where the nucleic acid
probes with a nonfluorescent molecule conjugates with a fluorophore after hybridization. In case
of indirect labeling, the molecule directly attached to the nucleic acid probe is typically either
biotin or a hapten, such as dinitrophenol (DNP) or digoxigenin (Figure 1.14.) [91].
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Figure 1.14. Principles of fluorescence in-situ hybridization (FISH).(a) The basic elements of
FISH are a DNA probe and a target sequence. (b) Before hybridization, the DNA probe is
labeled. Two labeling strategies are commonly used: indirect labeling (left panel) and direct
labeling (right panel). For indirect labeling, probes are labeled with modified nucleotides that
contain a hapten, whereas direct labeling uses nucleotides that have been directly modified to
contain a fluorophore. (c) The labeled probe and the target DNA are denatured. (d) Combining
the denatured probe and target allows the annealing of complementary DNA sequences. (e) If the
probe has been labeled indirectly, an extra step is required for visualization of the nonfluorescent hapten that uses an enzymatic or immunological detection system. This figure is
reproduced by permission from [88]. Copyright 2005, Nature Publishing Group.

FISH can be used for microbial research as well, for example identification, quantification
and characterization of phylogenetically defined microbial populations in complex environments
(Figure 1.15.) [90]. The in-situ hybridization is performed with fluorophore- or the hapten- or
biotin-labeled probe, after which the specimen is incubated with fluorophore-labeled antibody or
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avidin. But before direct or indirect labelling of flourophores, the probe nucleic acid must be
modified through chemical and enzymatic reactions. For example, a 3'-terminal Ribonucleotide
has been added to RNA probes or DNA probes, using terminal transferase [91].

Figure 1.15. Application of fluorescence in situ hybridization for microbial analysis. The sample
is first fixed to stabilize the cells and permeabilize the cell membranes. The labelled
oligonucleotide probe is then added and allowed to hybridize to its intracellular targets before the
excess probe is washed away. The sample is then ready for single-cell identification and
quantification by either epifluorescence microscopy or flow cytometry. This figure is reproduced
by permission from [90]. Copyright 2008, Springer Nature.
In order to preserve the nucleic acids in tissue or cells from the natural breakdown, of
cellular components, it requires a fixation step. Different types of fixatives are used, for example,
freezing, denaturing fixatives, cross-linking fixatives etc. Crosslinking fixatives, such as formalin,
are most commonly used in combination with FISH because the crosslinks retain morphology and
prevent loss of nucleic acid during the steps of the assay though it limits accessibility of the target
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nucleic acid to hybridize with the probe. To get the best results, some applications use a
combination approach, i.e., frozen or alcohol fixed sample is subjected to cross linking treatment
immediately prior to application of the probe [93]. After fixation, the intracellular targets go
through an incubation step in which fluorescent labelled probes diffuse to its intracellular targets
for a few hours and form specific hybrids in the chromosome [88].

Figure 1.16. FISH images for microbacterial analysis. (a–c) Confocal laser scanning
microscopy (CLSM) images showing PNA FISH of mixed planktonic bacteria labelled using
three PNA probes. (a) Universal bacterial probe (Bac-Uni1-CY3) showing that all bacteria stain
red. (b) P. aeruginosa probe (Psaer-FITC) showing that a proportion of the population stain
green. (c) Multiplex PNA staining of P. aeruginosa (yellow bacteria showing hybridization with
both universal and P. aeruginosa-specific probes), Staph. aureus (purple bacteria hybridized
with both universal and Staph. aureus-specific probes), and Micrococcus luteus and Strep.
oralis (red bacteria showing hybridization with the universal probe only). (d–g) Mixed bacterial
labelled using three PNA probes: (d) universal bacterial probe (red); (e) P. aeruginosa-specific
probe (green); (f) Staph. aureus-specific probe (blue); (g) multiplex PNA staining (overlay of d–
f). These figures are reproduced by permission from [92]. Copyright 2009, Microbiology
Society.
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The appended fluorophores from the hybrids provide the ability to visually detect the
homologous regions within the cellular structure using a fluorescence microscope. Other camera
with better resolution like photographic or electronic cameras can also be used to provide
permanent images of the fluorescence staining patterns, and the later can be used to provide
quantitative measurements of the probe fluorescence [91]. For microbial analysis, FISH permits
the visualization and identification of individual bacteria in human disease states in situ [92]. For
example,

a

study

was

carried

out

on

Staphylococcus

aureus D76, Streptococcus

oralis B52, Micrococcus luteus B81 and Pseudomonas aeruginosa D40 isolated from noninfected chronic venous leg ulcers (CVLUs) [92]. Fluorescently labelled highly specific two PNA
probes were hybridized to 16S rRNA of two bacterial species (P. aeruginosa, S. aureus) and the
third one 16S rRNA probe (Bac-Uni1-CY3) was used as a universal bacterial probe. Sections
hybridized with the PNA probes were viewed and analyzed by Confocal laser scanning microscopy
(CLSM) using a Leica TCS SP2 AOBS spectral confocal microscope (Figure 1.16.) [92]. For
multi-channel recordings, fluorochromes were scanned sequentially to eliminate spectral overlap
between probes [92].
To improve the detection sensitivity of fluorescent in-situ hybridization (FISH), different
types of amplification methods and probes with higher base number are used. For example, 600
copies of HPV-16 DNA in SiHa and CaSki cells were detected in FISH method along with
Tyramide Signal Amplification by using newly developed TSA reagents like cyanine 3 tyramide,
biotinyl tyramide and a biotin TSA Plus. This amplification method provided high level of
sensitivity by allowing detection of two single copies of integrated HPV-16 DNA in SiHa cells,
using small and defined probe with 619 bases [94].
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1.2.3 DNA Microarrays
DNA microarray is a glass slide or chip containing specific nucleic acid sequences (DNA)
spotted in an ordered two or three-dimensional matrix that enables the simultaneous detection of
target nucleic acids via hybridization [50, 53]. It can be used to detect DNA or RNA (most
commonly as complimentary DNA (cDNA) after reverse transcription), that may or may not be
translated into proteins. It is also used for gene expression profiling [96].
DNA arrays or chip can vary based on the nucleic acid segments anchored on the glass
support. Chips, containing large nucleic acid segments, usually greater than 100 bp, have been
primarily used to measure the expression levels of thousands of RNA species in cells or tissues
[96, 97]. If the chips have shorter segments of nucleic acid like 8-25 nucleotides, they may be used
in RNA expression level analysis in addition to mutational and comparative sequence analysis.
Chips with these shorter nucleic acids are known as oligonucleotide microarrays [98, 99].
Depending on the specific application or the types of DNA arrays used, the terms “probe”
and “target” can either refer to the arrayed nucleic acids or the nucleic acid sample in solution.
Here, in terms of gene expression profiling, nucleic acid on the surface of DNA array are
considered as “probes” and the nucleic acid in solution as “target” [101].
The first step of gene expression profiling starts with production of arrays where specific
‘probes’ will be printed on the array. In many cases, probes or nucleic acids of interest are chosen
directly from databases like GenBank or the resource backbones of the array technologies. Also,
full-length cDNAs, collections of partially sequenced cDNAs or randomly chosen cDNAs from
any library of interest can be used. Producing DNA from clones by PCR and printing them on chip
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is also preferable to produce arrays with a low redundancy of representation, so as to survey the
broadest possible set of genes (Figure 1.17.) [98].

Figure 1.17. cDNA microarray schematics: polymerase chain reaction (PCR) products
representing specific genes are robotically printed on a glass or plastic matrix. RNA samples
from lean and obese individuals are fluorescently labelled by a single round of reverse
transcription, and then competitively hybridized to the same array. Fluorescent scanners are used
for detection and the microarray data are analyzed with sophisticated computer programs. The
figure is reproduced by permission from [102]. Copyright 2001, The Nutrition Society.

The arrays can be manufactured using two distinct approaches. In one approach, the
purified probes are printed onto the support using either simple spotting techniques or
microfabricated ink jet pumps. The support can be made of glass or nitrocellulose. The second
approach involves synthesizing probes on the chip surface. In most cases, the DNA probes attached
on the support is ill-defined due to their intra-strand cross-linked and also due to some matrix
effects. It is therefore can be considered that oligonucleotide matrices, with their short chains and
single points of constraint at each chain end, may well be a far more accessible probe for
hybridization [98, 101].The next step is target preparation. It can begin with PCR amplification
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reactions using genomic DNA, RNA, or cloned templates. Random fragmentation of PCR products
can be preferable for hybridization by producing targets with accessible single stranded segments
[98, 101].
Single stranded RNA can be generated through in vitro transcription reactions using PCR
products with terminal RNA polymerase promoter sequences as templates. Although hybridization
of targets to microarray is typically diffusion controlled, it can be accelerated using spatially
defined electric fields which increase target concentration near the array surface.
Targets are usually internally labelled with fluorescent dyes or haptens at their 5′ or 3′ ends.
After hybridization, fluorescent signals are produced by exciting the array surface with a laser and
scanned using commercially available confocal microscopes equipped with either photon
multiplier tubes or CCD cameras [98, 101].
There are different approaches towards measuring gene expression using microarray. One
of the common applications is to compare expression of a set of genes from a cell maintained in a
particular condition (test condition) to the same set of genes from a reference cell (control
condition) [103]. If the RNAs are fluorescently labelled, the spots or pixels in the hybridized
microarray are excited by a laser and scanned at suitable wavelengths to detect appropriate
fluorophores. Theoretically, the intensity of fluorescence emitted upon excitation corresponds to
the amount of bound nucleic acid. For instance, if cDNA from test condition for a particular gene
was in greater abundance than that from control condition, the corresponding emission will be
brighter. Thus, at the end of the experimental stage, an image of the microarray can be seen, in
which each spot that corresponds to a gene has an associated fluorescence value representing the
relative expression level of that gene (Figure 1.17.). After measuring the expression level

35
compared to control and correcting the background, the data are normalized with respect to
housekeeping genes that will not change under these two conditions [103].
Microarray fluorescence is scanned and the pixel density (intensity) of each spot is
determined. The local background signal is subtracted automatically from the mean signal intensity
of hybridization signal of each spot. The fluorescence intensity from values for all replicates of the
negative control genes for whole-genome arrays are averaged, and then the averages were
subtracted from the background-corrected intensity values for the hybridization signals [104].
After measuring the signal intensity, a linear relationship between the signal intensity and
the initial amount of DNA is established. The unknown amount is then determined from a
calibration curve. The technology allows performing high scale and data intensive experiments as
it has high screening capacity of detecting relative abundance of nucleic acid in large sequence in
multiple genes [105]. A recently developed standard and custom-made phylogenetic microarray
“PhyloChip” consists of 500,000 oligonucleotide probes capable of identifying 8743 strains of
bacteria with good sensitivity without culturing [62, 67].
Some advantages and disadvantages of these three methods are summarized in Table 1.2.
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Table 1.2. Comparison of advantages and limitations of different quantitative methods for
nucleic acid
Method
qPCR

Advantages
• Highly sensitive
• Specific
• Provide accurate
quantitative
information [85]

FISH

• Robustness
• Multiplexing
capabilities [62, 65]

DNA
microarray

• High screening
capacity
• Can analyze high
throughput and
multiple miRNAs
simultaneously [62,
67, 106]

Limitations
• Requires time, careful calibration, consistent
source of material, suffers from matrix effect
• Require trained person
• Choice of signal threshold made by the operator
introduces subjectivity into the analysis
• Requires reference gene for normalization
• Inter lab variation can be substantial due to
differences in standard curve construction
• Expensive and difficult to carry on in field
conditions or in point of care environment[85]
[102, 104]
• Require extra amplification step due to low signal
[62, 65]
• Labor-intensive method [95]
• Require special instrumentation and software for
analyzing target [89]
• Low sensitivity. Require large amount of sample
for analyze
• Affected by density of probes and neighboring
DNA sequence respectively
• Optimized microarrays typically produce
repeatable relative quantitation of different nucleic
acid targets rather than absolute concentration [62,
67]

1.2.4 New Approaches to quantitative analysis of nucleic acids
To improve sensitivity, specificity, multiplicity of the available methods for quantitative
analysis of nucleic acids many advancements have been implemented. Recently new methods for
nucleic acid quantitation such as ligase chain reaction (LCR), rolling circle amplification (RCA),
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exponential isothermal amplification reaction (EXPAR), nuclease-assisted amplification, etc. have
been developed [105, 106]. Below some of the new methods for quantitative analysis of nucleic
acid are discussed.
1.2.4.1 Rolling Circle Amplification (RCA)
Rolling circle amplification RCA has been developed to improve sensitive diagnostic
methods for a variety of targets, including nucleic acids (DNA, RNA), small molecules, proteins,
and cells [107].
It is an efficient and simple isothermal enzymatic process in which a short DNA or RNA
primer is amplified to form a long single stranded DNA or RNA using a circular DNA template
and special DNA or RNA polymerases (Phi29, Bst, and Vent exo-DNA polymerase for DNA,
and T7 RNA polymerase for RNA). The RCA product is a concatemer (long continuous DNA
molecule with repeated units of the same DNA sequence linked in series) containing tens to
hundreds of tandem repeats that are complementary to the circular template. Since RCA products
can be tailor-designed by manipulating the circular template, RCA has been employed to
generate complex DNA nanostructures such as DNA origami, nanotubes, nanoribbons and DNA
based metamaterials which have been utilized for biodetection, drug delivery, designing
bioelectronic circuits, and bioseparation [107].
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Figure 1.18. Schematic illustration of the basic methods RCA circularized DNA template. (A)
Making a DNA circle by template-mediated enzymatic ligation. (B) Linear RCA reaction to
generate long ssDNA with template and target nucleic acids. (C) Linear RCA reaction to
generate long RNA with a pre-made DNA circular template. (D) Multiprimed RCA to generate
multiple copies of the RCA product from a single circle. (E) Exponential DNA amplification by
hyper-branched RCA. (F) Exponential DNA amplification generating multiple circles from the
RCA products (G) Exponential DNA amplification by primer generation using nicking enzymes.
The figure is reproduced by permission from [107]. Copyright 2014, Royal Society of
Chemistry.

The target DNA and RNA can be used as a ligation template to circularize a padlock
probe that is used as the circular template (Figure 1.18.). This circular DNA template is usually
synthesized via template mediated enzymatic ligation (e.g., T4 DNA ligase) or template-free
ligation using special DNA ligases. For RNA, a sequence that is complementary to primer (e.g.,
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T7 promoter) sequence is added to the circle which then annealed to the circular template.
Transcription is then carried out by RNA polymerase in the presence of nucleotide triphosphates
(NTPs) instead of dNTPs. By designing the circular template and primers, the length, sequence,
composition, structure, and rigidity of the RCA product can be finely tuned, making RCA a
highly versatile technique [107].

Figure 1.19. Quantification of RCA product. Molecular recognition of DNA or protein targets
through padlock probe ligation or proximity ligation results in the formation of a unique circular
DNA molecule with 20 nm diameter. Fluorescent molecule–tagged probes are hybridized to the
repeated sequence, resulting in a confined cluster of up to 1,000 fluorophores, visible in a
fluorescence microscope. Individual DNA molecules are detected and quantified by pumping a
sample through a thermoplastic microchannel mounted in a standard confocal fluorescence
microscope operating in line-scan mode. Hybridization of detection probes of distinct colors
allows multiplexed signal readout. The raw data files were thresholded to generate a binary
output file, which allows counting and classification of individual objects. The figure is
reproduced by permission from [111]. Copyright 2006, Springer Nature.
A promising feature of RCA is capability for exponential amplification based on how
the circular templates are designed (Figure 1.18. D–G). It can be done by initiating multiple
amplification events by employing multiple primers that hybridize with the same circle, producing
multiple RCA products (‘‘Multiprimed RCA’’ Figure 1.18. D) [108-110].
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The number of primers that can bind with the circular template depends on length of primer
or template. Another way to amplify the product in exponential manner is the so-called
hyperbranched RCA (HRCA) (or ramification amplification) where the RCA product is used as
the template for further amplification with the second and third sets of primers (Figure 1.18. E)
[110]. Combination of strategies can be integrated to improve the sensitivity, especially in order
to targets in low abundance. A linear RCA product can be converted into multiple circles using
restriction enzyme digestion followed by template mediated enzymatic ligation. These new circles
can then be employed for further amplification using a second primer set (Figure 1.18.) known as
‘‘circle-to-circle amplification’’ process which can be repeated for additional amplification [110].
Another method has been developed where RCA can be used to generate multiple primers
by treating the RCA product with nicking enzymes upon hybridization with the second set of
circles and for further RCA amplification [110].
RCA’s variations have been developed for detecting and quantifying the amplified product
obtained. One of them is the Single Molecule Detection (SMD) based method (Figure 1.19.). To
make the product visible, it was labeled with short fluorescent molecule–tagged hybridization
probes [111]. The individual RCA products are counted when they are pumped through a
thermoplastic microchannel mounted in a standard confocal fluorescence microscope operating in
line-scan mode. Various circles can be formed corresponding to unique analyte entities and
amplified in the same reaction. Hybridization of detection probes of distinct colors allows
multiplexed signal readout. The quantitative dynamic range of the amplified single molecule
readout format was investigated by preparing a serial dilution series of DNA circles and from the
linear regression, the quantity can be determined [110].
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1.2.4.2 Nanomaterials-Based Nucleic Acid Detection
Nanomaterials possess a variety of advantages as biomolecular detectors due to its unique
photoelectric properties, size effect, and surface effect that can be tuned to a particular application.

Figure 1.20. Nanomaterial-based approaches for rapid nucleic acid analysis. Each of the
approaches has single multiple signal transduction pathways like optical, electrical conductance,
electrochemical, electrochemical, electrical conductance, Surface plasmon resonance (SPR) etc.
to detect the hybridized targets. This figure is reproduced by permission from [11]. Copyright
2017, American Chemical Society.

Use of nanomaterials has allowed developing direct detection assays for nucleic acids that can
compete with enzymatic approaches like PCR with high sensitivity (aM concentrations being
detectable) [11]. For all of these reasons, nanomaterial enabled assays or nanomaterial based
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nucleic acid biosensors continue to be popular and are breaking performance records related to the
speed and sensitivity of nucleic acids detection [11, 106].
Different types of nanomaterial based probes have been developed for detection and
quantification of nucleic acid. These nanomaterial sensors can be summarized in following groups
(Figure 1.20.) [11].
1. Metal nanoparticles
2. DNA nanostructures
3. Carbon nanotubes
4. Silicon nanowires
5. Nano structured electrodes
1.2.4.2.1. Nucleic Acid Biosensors Based on Gold Nanoparticle Probes.
Multifunctional gold nanoparticle (Au-NP) based probes are used widely to develop
effective biosensors. Recently, a disposable nucleic acid biosensor (DNAB) based on the
oligonucleotide functionalized Au-NPs in the form of a lateral flow nucleic acid (LFNA) test strips.
Oligonucleotide functionalized gold nanoparticles (Au-NPs) allows visual detection of DNA via
surface plasmon resonance (SPR). It is a surface-sensitive analytical technique based on the ability
to detect dielectric constant changes induced by molecular adsorption at a noble metal film. This
technique has been widely used in biomolecular interaction studies. Usually to increase the
magnitude of the response in SPR, a second specifically interacting biomolecule is introduced.
Often this second, “probe”, molecule carries a high molecular weight or high refractive index tag.
Colloidal Au nanoparticles are of great use in this molecular recognition experiment as it has high
density, large dielectric constant, and biocompatibility. Upon hybridization of Au-NP tagged
oligonucleotide, it increases the SPR reflectance and hence makes easier to detect hybridization
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[112]. This disposable nucleic acid biosensor has been reported for low-cost and sensitive
detection of nucleic acid samples in 15 minutes by combining the unique optical properties of gold
nanoparticles (Au-NP), high efficiency of chromatographic separation and sandwich type DNA
hybridization reactions [113].

Figure 1.21. Illustration of DNAB and quantitative analysis (a) Measurement principle of the
DNAB (b) Calibration curve of the DNAB with different concentrations of target DNA. This
figure is reproduced by permission from [113]. Copyright 2009, American Chemical Society.

The lateral flow strip (Figure 1.21. (a)) consists of sample application pad, Au-NP-DNA or
HRP-Au-NP-DNA conjugate pad, nitrocellulose membrane, and absorbent pad supported on a
backing layer. Three DNA probes were used: DNA probe 1 and DNA probe 3 were immobilized
on the nitrocellulose membrane to immobilize the capture and control streptavidin-biotin DNA
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conjugates (test zone and control zone, respectively). DNA probe 2 was attached to the Au-NPs
and dispensed in the conjugate pad (glass fiber) [113].
The sample solution containing target DNA is applied on the sample application pad, then
the solution migrates by capillary action to conjugate pad where the solution rehydrated the AuNP-DNA probe 2 conjugates and the target DNA hybridized with DNA probe 2 of the conjugates
to form the complex and continue to migrate along the strip. Second hybridization took place
between the target DNA and the immobilized DNA probe 1 on the test zone where the hybrids are
captured. The accumulation of Au-NPs in the test zone of the nitrocellulose membrane is
visualized as a characteristic red band as it increases the reflectance of SPR. The excess of AuNP-DNA probe 2 conjugates continue to migrate and pass the control zone, in which the DNA
probe 3 is immobilized. Here hybridization events between the DNA probe 2 and the DNA probe
3 takes place and captured excess of Au-NP-DNA probe 2 conjugates, forming a second red band
[114]. If there is no target DNA, no red band is observed in the test zone [113].
Thus, formation of red band enables qualitative analysis, while quantitative analysis is
realized by reading the optical intensity of the test line with the portable strip reader (Figure 1.21.
(a)). The peak areas increased with the increase of DNA concentration. The unknown
concentration of target then determined from calibration plot. The detection limit of this approach
is 0.5 nM (based on S/N = 3) estimated with the 15 minutes assay time. For human genomic DNA
direct analysis, detection limit is 2.5 µg/mL (1.25 fM for genomic DNA) by adopting welldesigned DNA probes (Figure 1.21. (b)) [113].
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Comparison of the detection target nucleic acid amount of different quantitative approaches are
discussed in Table 1.3.
Table 1.3. Comparison of detection amount of different quantitative method for nucleic acid

Method

Target

Reference

DNA from human
blood

Amount
<0.1ng/µl in Total
RNA
.01ng/µl to
15ng/µl

quantitative RT-PCR

mRNA

quantitative PCR
micro array

mRNA

20 µg total RNA

[117]

FISH

HPV-16 DNA

600 copies

[118]

In-SITU Hybridization

genomic-DNA

repetitive, 40 KB

[119]

Disposable Nucleic Acid
Biosensors Based on Gold
Nanoparticle Probes

DNA

50 pM to 100 nM

[113]

RCA

DNA

<100 pM

[111]

[115]
[116]

1.3 An alternative approach towards quantitative analysis of nucleic acids
After reviewing established approaches for quantitative analysis of nucleic acids, we
identified two major shortcomings: need of calibration and elaborate equipment. Usually nucleic
acid quantification requires calibration established for the particular system where signal
magnitude generated by an unknown sample is correlated to that calibration to get corresponding
quantitative measurement (Figure 1.22.). However, any calibration itself comes with limitations
like need of a pure, quantitatively characterized standard of a target (or reference gene with
identical quantitation efficiency) [82]. Matching the calibration conditions/environment like lab to
lab, background to background, reagent to reagent, etc. to the target assay is also necessary for
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absolute quantification of nucleic acid as the value of the signal magnitude is often affected by
the calibration conditions and matrix effects. For example, in microarray, density of probes, effects
of surface DNA concentration on fluorophores and other effects make establishing absolute
calibration impossible to control with necessary precision, hence it affects the value of target
concentration [62].

Figure 1.22. Calibration for getting quantitative information of unknown from signal magnitude.
This figure is reproduced by permission from [120]. Copyright 2018, American Chemical
Society

Though the golden standard for speciﬁc nucleic acid quantitation qPCR does provide
information on a target amount, it is rather time-consuming, requires speciﬁc instrumentation, and
after all, suffers from matrix effects affecting quantitation reliability which eventually makes the
approach expensive. While less expensive, other approaches (i.e., microarrays, in-situ
hybridizations) are less reliable, especially when it concerns discerning accurate quantitative
information [27, 66]. As a consequence, these limitations make the approach difficult to
accomplish in many circumstances.
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Therefore, we hypothesized that it would be beneficial to obtain quantitative information
not from an absolute signal/calibration pathway but from another characteristic feature that can
ideally mitigate uncertainties associated with matrix effects and obviate use of standard. Such
feature can be the position of the response profile. Here, it is shown for a target at concentration
2 in Figure 1.23, that even if experimental factors affect the signal magnitude, the target’s quantity
can be reliably determined from the position of its response proﬁle (i.e., peak maximum). Ideally,
if the response profile (rather than the absolute response) can be correlated with target amount, the
quantitation approach will be beneficial. In next chapters, we will discuss on developing a targetprobe binding mechanism based on a negative cooperativity eﬀect in order to generate response
profile. Here, in this study, position of inflection point will be indicating the to amount of single
stranded nucleic acid as target.

Figure 1.23. Alternative approach for nucleic acid quantification. It can be based on assessing an
unknown target’s response proﬁle and obtaining quantitative information from a position of a
response proﬁle feature such as a peak maximum . This figure is reproduced by permission from
[120]. Copyright 2018, American Chemical Society
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CHAPTER 2
ALTERNATIVE APPROACH FOR QUANTITATION: RESPONSE PROFILE
2.1 Developing Response Profile for Quantitation
As we hypothesized that it would be beneficial to the obviate use of standard, we came up
with an idea to generate a response profile that can be correlated to target amount. Hence, the
ultimate goal of the project is to develop a new general concept for the quantitative assessment of
various bioanalytical targets that obviates the need for standard and mitigates the matrix effects.
Developing a methodology that positions the response proﬁle as a function of the target’s
quantity is rather challenging. To do it, one needs to establish a target probe binding model that
yields a response proﬁle which uniquely deﬁnes the target amounts. To the best of our knowledge,
no such capability exists to date.
In this work, we established an approach for absolute quantitation of nucleic acids based
on the position of the inflection point as an indicator of the target amount (Figure 2.1.B). To enable
the capability, we deliberately designed a sensing system based on a mechanism for negative
cooperativity with limited receptor concentration [121]. Negative cooperativity is a phenomenon
in which the binding of one or more ligand molecules to a target with multiple binding sites
decreases the target’s affinity toward subsequent binding events.
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It has been demonstrated both theoretically and practically that when a ligand binds to the
receptor with high affinity and decreases the affinity of second binding event (negative
cooperativity effect), then a highly ultrasensitive response with a pronounced threshold is
generated [121]. We demonstrated that the position of the ultrasensitive response resulting from
such a system is indicative of a target amount. Therefore, the model can be employed for the
calibration-less quantitation of target nucleic acid.
Particularly our system consists of two probes that bind to the target as receptors with
similar affinity. The probes are present in equimolar amounts and each probe can bind the target
separately or both probes can bind it simultaneously. However, by design, the binding of one probe
to the target decreases the affinity of another (negative cooperativity effect) (Figure 2.1.A). It
means that in the presence of the target and both probes, formation of 1:1 target-probe hybrid is
more favorable than formation of a 1:2 target-probe hybrid.
Therefore, if the target is exposed to various amounts of probes present equimolarly, 1:1
target-probe hybrids preferentially form when the total concentration of the probes is below the
concentration of the target (Figure 2.1.B, total probe concentration of 6 or below). However, when
the total concentration of the probes exceeds concentration of the target, 1:2 target-probe hybrids
start forming (Figure 2.1.B, total probe concentration above 6). In this case, if there is a signal
transduction pathway that discerns 1:2 target-probe hybrids over the target, unbound probes and
1:1 target-probe hybrids, the change from 1:1 hybrid (no signal) to 1:2 hybrid (signal) shows an
inﬂection point which indicates that the total concentration of probes exceeds the target’s
concentration.
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Figure 2.1. Binding of probe to target. In the quantitation approach, two probes bind the same
target with similar (or identical) affinity but with a negative cooperativity effect. The negative
cooperativity causes binding of one probe to decrease target’s affinity toward another probe (A).
(B) If an unknown amount of target is exposed to varying concentrations of probes (present
equimolarly), 1:1 target−probe hybrids will preferentially form. The 1:2 target−probe hybrids
will form only when the total probe concentration exceeds target concentration (i.e., probe
concentration above 6 in the example). Assuming signal transduction mechanism that is capable
to discern 1:2 hybrids, the signal inﬂection on response proﬁle (“inﬂection point”) with respect to
probe concentration indicates the target concentration. This figure is reproduced by permission
from [120]. Copyright 2018, American Chemical Society

2.2. Binding Mechanism: Theoretical consideration
The theory of this binding mechanism was developed based on the elegant theoretical
discussion from Ha and Ferrel’s Science paper [121].
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𝐾𝑇→𝑇𝑃1

𝑇 + 𝑃1 ↔

𝐾𝑇→𝑇𝑃2

𝑇 + 𝑃2 ↔

𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2

𝑇𝑃1 + 𝑃2 ↔
(A)

𝐾𝑇𝑃2 →𝑇𝑃1 𝑃2

𝑇𝑃2 + 𝑃1 ↔
(B)

𝑇𝑃1 𝑃2
𝑇𝑃1 𝑃2

Figure 2.2. Schematic view of the sequential binding of two complimentary probes (P1 and P2) to
a stable template (T) with limited concentration. The binding events can start independently with
any of the probe where in Scheme (A), the first binding event starts with P1 and in Scheme (B),
the second binding starts with P2.

The sequential binding of two probes P1 and P2 to a stable complimentary template T,
shown schematically in Figure 2.2. can be described by two equilibrium expressions:

𝐾𝑇→𝑇𝑃1 =

2 𝑇∙𝑃1

𝐾𝑇𝑃1→𝑇𝑃1𝑃2 =

𝑇𝑃1
𝑇∙𝑃1 ∙𝑃2
2𝑇𝑃1 𝑃2

Eq 1
Eq 2

The binding cooperativity can be characterized by c, where the parameter c= 𝐾𝑇→𝑇𝑃1 /
𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 . ‘K’ is the dissociation constant of binding event. If the two dissociation constants are
equal, the binding events can be viewed as independent; if the first binding is weaker than the
second (𝐾𝑇→𝑇𝑃1 > 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 ), there is positive cooperativity; and if the first binding reaction is
stronger than the second binding (𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 > 𝐾𝑇→𝑇𝑃1 ), there is negative cooperativity.
Therefore, c < 1 corresponds to negative cooperativity and c > 1 to positive cooperativity.
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The factors of 2 in Eqn 1 and 2 come from the fact there are two equivalent probe template
hybrid TP1P2 (since binding event can start with either probe P1 or P2). For our purposes, it is
convenient to express one of the dissociation constants in terms of the cooperativity c and the
other dissociation constant; Eq 1 becomes:

2 𝑇∙𝑃
𝑐𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 = 𝐾𝑇→𝑇𝑃1 . 𝑇𝑃 1
1

Eq 3

In the classical treatments of this system, one adds a conservation equation:

𝑇𝑡𝑜𝑡 = 𝑇 + 𝑇𝑃1 + 𝑇𝑃1 𝑃2

Eq 4

making the implicit assumption that probe P1 is not appreciably depleted by its binding to the
target. It follows that

𝑇

=

𝑇𝑡𝑜𝑡

𝑇𝑃1
𝑇𝑡𝑜𝑡

=

𝑇𝑃1 𝑃2
𝑇𝑡𝑜𝑡

=

2
𝑐𝐾𝑇𝑃
1→𝑇𝑃1 𝑃2
2
𝑐𝐾𝑇𝑃
+2𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 𝑃1 +𝑃1 𝑃2
1 →𝑇𝑃1 𝑃2

2𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 𝑃1
2
𝑐𝐾𝑇𝑃
+2𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 𝑃1 +𝑃1 𝑃2
1 →𝑇𝑃1 𝑃2

𝑃1 𝑃2
𝑐𝐾 2

𝑇𝑃1 →𝑇𝑃1 𝑃2 +2𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 𝑃1 +𝑃1 𝑃2

Eq 5

Eq 6

Eq 7

We wish to solve for T, TP1, and TP1P2 in terms of Ttot, Ptot, c, and 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 where

Ptot = P1 +TP1 + 2TP1 P2

Eq 8
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To solve for TP1P2, we first eliminate the variables T, TP1, and P1, yielding:
2
𝑐 2 𝐾𝑇𝑃
𝑇𝑃1 𝑃2 + 4𝑇𝑃1 𝑃2 (2𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 𝑇𝑃1 𝑃2 + (𝑃𝑡𝑜𝑡 − 𝑇𝑃1 𝑃2 − 𝑇𝑡𝑜𝑡 )(𝑇𝑃1 𝑃2 − 𝑇𝑡𝑜𝑡 )) +
1 →𝑇𝑃1 𝑃2

𝑐((𝑃𝑡𝑜𝑡 − 2𝑇𝑃1 𝑃2 )2 (𝑇𝑃1 𝑃2 − 𝑇𝑡𝑜𝑡 ) + 2𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 𝑇𝑃1 𝑃2 (𝑃𝑡𝑜𝑡 − 4𝑇𝑃1 𝑃2 − 2𝑇𝑡𝑜𝑡 )) = 0

Eq 9

This equation implicitly defines TP1P2 as a function of Ttot, Ptot, c, and 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 . It can also be
solved, yielding either TP1P2 as an explicit function of Ttot, Ptot, c, and 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 or Ptot as a
function of Ttot, TP1P2, c, and 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 .
In case of very high affinity binding, we can simplify Eq 9 by ignoring terms of order
𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 and higher and solving for TP1P2. The resulting cubic equation yields three solutions
for c ≠ 1:
Eq 10

𝑇𝑃1 𝑃2 = 𝑇𝑡𝑜𝑡

𝑇𝑃1 𝑃2 =

𝑇𝑃1 𝑃2 =

(𝑐−1)𝑃𝑡𝑜𝑡 +𝑇𝑡𝑜𝑡 −√−(𝑐−1)𝑃𝑡𝑜𝑡

2

+2(𝑐−1)𝑃𝑡𝑜𝑡𝑇𝑡𝑡+𝑇𝑡𝑜𝑡 2

2(𝑐−1)

+2(𝑐−1)𝑃𝑡𝑜𝑡𝑇𝑡𝑜𝑡+𝑇𝑡𝑜𝑡 2
2(𝑐−1)

(𝑐−1)𝑃𝑡𝑜𝑡 +𝑇𝑡𝑜𝑡 +√−(𝑐−1)𝑃𝑡𝑜𝑡

Eq 10

2

Eq 11

Eqs 10 and 11 are physically relevant (i.e., they yield non-negative concentrations) for certain
ranges of Ttot and Ptot.
In the limit where the system has very strong negative cooperativity (c →0), Eq 10 reduces
to
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1

𝑇𝑃1 𝑃2 = 2 (𝑃𝑡𝑜𝑡 − 𝑇𝑡𝑜𝑡 ± (𝑃𝑡𝑜𝑡 − 𝑇𝑡𝑜𝑡 ))

Eq 12

The non-negative solutions of equation 10 are plotted in Figure 2.3. The shape of the
response profile confirms the model discussed previously.

(TP1P2)

Ttot = Ptot
(Ptot)
Figure 2.3. Graphical representation of relation between concentration of 1:2 target-probe hybrid
and total probe concentration. This figure is reproduced by permission from [120]. Copyright
2018, American Chemical Society

Inflection point is the area where transition from background plateau (no signal due to 1:2
hybrids) to area of increasing signal starts. It can be represented in different ways based on
measured parameter (Figure 2.4.) detection of this point manifests the unknown target
concentration. Hence, this inflection point is considered as the characteristic feature or a response
profile of the target concentration.
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Figure 2.4. Different graphical representations of inflection curve with different parameters
being indicative of 1:2 hybrid formation. This figure is reproduced by permission from [120].
Copyright 2018, American Chemical Society

2.3 Response profile based approach for quantitation of oligonucleotides
2.3.1 Binding Model for Quantitative Approach
For the proof-of-concept, we designed a sensing system for detection of single stranded
DNA as an oligonucleotide target based on the nucleic acid system reported in ref. 121. We
designed two oligonucleotide probes for ssDNA target that are complementary to the target and
have close binding affinity. However, the probes are designed in such way that both of them have
an overlapping binding region. This overlapping binding regions of the two probes imposes the
negative cooperativity effect: when one probe is bound to the target (Figure 2.5.) binding aﬃnity
of another probe decreases. As a consequence, formation of a 1:1 target-probe hybrid is a more
favorable than formation of 1:2 target-probe hybrid.
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Figure 2.5. Probes design for target to get response profile. Probes for an oligonucleotide target
are designed the way that while a target can bind both probes, the binding of each individual
probe decreases binding aﬃnity of another probe (due to binding region overlap, blue shade.
This figure is reproduced by permission from [120]. Copyright 2018, American Chemical
Society
To enable separation-free signal transduction, both probes are labeled with ﬂuorophores
(FRET pair) the way that FRET is eﬃcient only when both probes are in proximity (i.e., in 1:2
target−probe hybrid).
2.3.1.1 Fluorescence Resonance Energy Transfer (FRET)
FRET is an energy transfer mechanism between two fluorescent compounds or
fluorophores. This mechanism is of great importance for gaining a good understanding of some
biological systems since it provides an insight on distances between fluorophores. Here, one
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fluorophore absorbs the energy due to the excitation of incident light and transfer excitation state
energy to another fluorophore in a non-radiative manner. A pair of molecules that interact in such
a manner that FRET occurs is often referred to as a donor/acceptor pair. The Jablonski diagram
(Figure 2.6.) illustrates the transitions of energy between the donor (D) and the acceptor (A) in
FRET. The transition of energy explained below:
D+ hυ → D* [D→ donor, D*→donor after absorbing energy, hυ → energy].
D* + A → D + A* [A →Acceptor, A* →Acceptor after absorbing energy from excited donor
D*].
A*→ A + hυ´ [Here excited acceptor A* emitting energy].
Energy transfer causes the reduction of intensity of donor fluorescence along with an increase in
acceptor fluorescence intensity [80, 118].

h𝞴

Figure 2.6. Jablonski diagram illustrating the FRET process. Here donor became excited after
absorbing energy (D→ donor, D*→donor after absorbing energy), and transfer excitation state
energy to a nearby chromophore, the acceptor in a non radiative manner (A →Acceptor, A*
→Acceptor after absorbing energy from excited donor D*). This figure is reproduced by
permission from [122]. Copyright 2009, arXiv.org.
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The primary conditions for FRET to be efficient are overlap between the absorption spectrum of
acceptor and the fluorescence emission spectrum of the donor (Figure 2.7.) and close proximity
between donor and acceptor molecules (typically 10–100 Å) [123]. The distance at which the
energy transfer efficiency is 50% is known as Förster distance, R0. It depends on the
overlap integral of the donor emission spectrum with the acceptor absorption spectrum and their
mutual molecular orientation, which can be expressed by the following equation
𝑅06

2.07 𝜅 2 𝑄𝐷
=
∫ 𝐹𝐷 (𝜆) 𝜖𝐴 (𝜆)𝜆4 𝑑𝜆
5
4
128𝜋 𝑁𝐴 𝑛

where QD is the fluorescence quantum yield of the donor in the absence of the acceptor, 𝜅 is the
dipole orientation factor, 𝑛 is the refractive index of the medium, 𝑁𝐴 is Avogadro's number. the
spectral overlap integral J is calculated as
∫ 𝑓𝐷 (𝜆)𝜖𝐴 (𝜆)𝜆4 𝑑𝜆
𝐽=
= ∫ ̅̅̅
𝑓𝐷 (𝜆) 𝜖𝐴 (𝜆)𝜆4 𝑑𝜆
∫ 𝑓𝐷 (𝜆) 𝑑𝜆
where 𝑓𝐷 is the donor emission spectrum, ̅̅̅
𝑓𝐷 is the donor emission spectrum normalized to an area
of 1, and 𝜖𝐴 is the acceptor molar extinction coefficient normally obtained from an absorption
spectrum [124].
To evaluate differences in FRET, a ratio of donor emission to acceptor emission are measured.
When D and A are in close proximity, emission of the donor decreases, and emission of acceptor
increases. Therefore, the change in Donor/Acceptor ratios on their emission spectrum are
observed.
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Figure 2.7. Absorption and fluorescence spectra of a typical donor-acceptor pair. Brown region is
the spectral overlap between the fluorescence spectrum of donor and absorption spectrum of
acceptor. This figure is reproduced by permission from [122]. Copyright 2009, arXiv.org.

2.3.1.2 Design of FRET Based Signal Transduction for Quantitative analysis of oligonucleotides
As a distance dependent mechanism, FRET is efficient enough to observe the changes in
distance between two sites labelled with suitable fluorophore pair [122].

Figure 2.8. Excitation and emission spectra of FAM and TMR as donor and acceptor. Acceptor
fluorescence intensity increases in presence of donor due to spectral overlap.
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We used FRET as our signal transduction pathway to observe the formation of 1:2 targetprobe hybrids. In our system, if one probe was labelled with donor and another with acceptor, the
FRET would be efficient only when both probes are in close proximity to each other in 1:2 targetprobe hybrid. Free probes and 1:1 hybrid do not bring the donor and acceptor in close proximity
and do not produce efficient FRET (Figure 2.10). We chose fluorescein amidite (FAM)
fluorophore as the donor and Tetramethyl Rhodamine (TMR) as the acceptor since emission of
FAM (490-700 nm) overlaps with absorption of TMR (500-600 nm) (Figure 2.9.) [119].

(a)

(b)

Figure 2.9. Signal transduction from the binding model(a) Probes for an oligonucleotide target
are designed and are labelled with flourophores the way that while a target can bind both probes,
the binding of each individual probe decreases binding aﬃnity of another probe (due to binding
region overlap, blue shaded box) (b) We use changes in FRET rates as an indicator of 1:2
target−probe hybrid formation. This figure is reproduced by permission from [120]. Copyright
2018, American Chemical Society
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Therefore, no changes are expected before 1:2 hybrid forms. When 1:2 hybrid forms, D/A starts
decreasing.

CHAPTER 3
EXPERIMENTAL PROCEDURES
3.1 Reagents and Materials
All the chemical reagents were obtained from established commercial suppliers (i.e.,
SigmaAldrich [St. Louis, MO], Fisher Scientific [Pittsburg, PA] and others).

All the

oligonucleotides were obtained from IDT (Coralville, IA). The oligonucleotides’ sequences are
included in Table 3.1. Nuclease-free water used for preparation of DNA solutions was obtained
from IDT (Coralville, IA). The hybridization buffer (10 mM Tris-HCl, 1 mM EDTA, 50 mM
NaCl, pH 8.0) was prepared in house. The pH-meter calibration buffers (4.00±0.01, 7.00±0.01,
and 10.00±0.02) were purchased from Fisher. The sequences of Probes, Templates are given
below:
Table 3.1. Sequences of Oligonucleotides
Name of oligonucleotide

Sequence

Target Template (current system)

5’-TATTTCTTATTCATATTCAGGAAGACATCCAGACCAGGGCAC-3’

Probe (labeled with TMR at 3’
end)(current system)
Probe (labeled with FAM at 5’ end)

5’-GTGCCCTGGTCTGGATGTCT-3’

Random DNA

5’-AACAATACACTGACCCTGGACCTGAATGAACTTAAGACGAGC-3’

Target Template (new system)

5’-TAT TTCTTATTCATATTCAGGAAGACATCCAGACCAGGGCACGC-3’

Probe (labeled with TMR at 3’
end)(new system)

5’-GCGTGCCCTGGTCTGGATGTCT-3’

5’- ATGTCTTCCTGAATATGAATAAGAAATA -3’
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3.2 Sample Preparation
All the oligonucleotides (template/probes) obtained from IDT were reconstituted with
water to yield approx. 100 µM solutions. For each sample set, 0.5-1 µM working stock solutions
of target (and/or random DNA), probe 1 and probe 2 were prepared in hybridization buffer. Actual
concentrations of the stocks used to prepare every sample set were determined from absorption
spectra acquired on a Cary 4000 UV-vis spectrometer (Agilent Technologies, [Santa Clara, CA]).
Absorption at 260 nm and corresponding extinction coefficients provided by IDT were used to
calculate the actual concentrations of the solutions.
To establish a correlation between the target concentration and response profile, a set of
samples (usually 16 samples for each set) consisted of solutions with a defined target concentration
and various total probe concentrations present in an equimolar amount. The total probe
concentration range for the samples was designed to cover the target concentration, have an initial
and end plateau established, and ensure several data points on the transition slope. An example of
sample preparation is shown in Table 3.2. For measurement purpose, we prepared three replicates
for each sample set. A typical sample (500 µL) was prepared in a hybridization buffer from
relevant amounts of the target (and/or random DNA) and Probe 1 and Probe 2 working stock
solutions. The resulting solutions were denatured at 95°C in a thermostat for 15 minutes followed
by slow (overnight) cooling to room temperature (around 20°C). This temperature will allow
complete hybridization [126]. The denaturation step was necessary to eliminate secondary
structures to ensure ultimate probe-target binding.
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Table 3.2. Sample Preparation for a Target Concentration (i.e., 40 nM)
Sample Total Probe
number conc. (nM)

buffer volume
(µl)

s1
s2
s3
s4
s5
s6
s7
s8
s9
s10
s11
s12
s13
s14
s15
s16

404
400
396
392
384
380
376
372
368
364
360
356
352
348
340
332

16
20
24
28
36
40
44
48
52
56
60
64
68
72
80
88

Template
volume (µl)
Working stock
solution
2.5x10-07 M
80
80
80
80
80
80
80
80
80
80
80
80
80
80
80
80

Probes volume (µl)
Working stock
solution for each
probe
2.5x10-07 M
16
20
24
28
36
40
44
48
52
56
60
64
68
72
80
88

3.3 Instrumentation
After cooling down the samples, the emission spectra of solutions were recorded on a
spectrofluorimeter. Typically, measurements were performed on a 500-μL aliquot of sample
solution using a 1 cm optical path cuvette. To measure the emission from samples, we used three
different fluorimeters based on availability. The model number of the instruments are given below:
1. RF-6000 (Shimadzu, [Kyoto, Japan])
2. FluoroMax-4C (Horiba [Edison, NJ])
3. Quantum Master 8075 (Horiba, [Edison, NJ])
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3.3.1 Fluoroscence Spectroscopy
Fluorescence spectroscopy is an analytical method based instrument for measuring the
intensity and spectra of the fluorescent light emitted from a sample. In our system, we used a
standard xenon lamp to illuminate the sample for getting the emission spectra. The light pass
through a slit to the excitation monochromator where radiation of a target excitation wavelength
is isolated. A cell with sample solution was placed into the light path. The fluorophore in the
sample was excited and emitted light in every direction. The collected fluorescence emission
passed a slit entering the emission monochromator. Here, the emission wavelengths were isolated
and the emission at every wavelength was measured in a photomultiplier or detector which is
usually placed at 90° to the incident light beam to minimize the risk of transmitted or reflected
incident light reaching the detector. Photomultiplier transduced photons into measurable signal
like electric current. This emission spectrum is the raw data [125].

Figure 3.1. Schematic overview of fluorometer.
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A schematic overview of a fluorometer is shown in Figure 3.1. The resulting emission spectra are
used to calculate ratio as maximum emission of donor to maximum emission of acceptor [122,
123].
3.4 Sample analysis
We recorded the emission spectra of hybridized samples at room temperature. The
excitation wavelength was set at 490 nm as one providing efficient excitation of donor (FAM) and
negligible direct excitation of acceptor. Emission wavelength range 500-650 nm included emission
of both donor and acceptor [123].

CHAPTER 4
MODEL VALIDATION: CORRELATION BETWEEN RESPONSE PROFILE AND TARGET
AMOUNT
4.1 Analytical measurements
The ultimate goal of the project was to establish a quantification model based on the
position of a response profile. While assessing the approach, we analyzed different sets of samples
for various target concentrations where the samples from each set contained a fixed amount of
target with a ranges of probes concentrations (i.e., Table 3.2.).
All the emission spectra were corrected for buffer background. The example of emission
spectrum from each sample set is in Figures 4.1. to 4.7. After observing the emission spectra from
a set, we saw that as the probe concentration increased, the emission intensity kept increasing.
However, with respect to emission profile after a certain point, it started changing (increase of
relevant emission intensity of TMR) due to FRET. The changes in transition pattern in spectra is
even more clear after normalization (Figures 4.1 to 4.7.).
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(a)

(b)
Figure 4.1. Original spectra corrected for background (a) and normalized spectra (b) for 20 nM
target concentration and total probe concentration range 8 nM-52 nM. This figure is reproduced
by permission from [120]. Copyright 2018, American Chemical Society
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(a)

(b)
Figure 4.2. Original spectra corrected for background (a) and normalized spectra (b) for 40 nM
target concentration and total probe concentration range 20 nM- 104 nM. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society
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(a)

(b)
Figure 4.3. Original spectra corrected for background (a) and normalized spectra (b) for 80 nM
target concentration and total probe concentration range 20 nM- 208 nM. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society
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(a)

(b)
Figure 4.4. Original spectra corrected for background (a) and normalized spectra (b) for 130 nM
target concentration and total probe concentration range 20 nM - 260 nM. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society
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(a)

(b)
Figure 4.5. Original spectra corrected for background (a) and normalized spectra (b) for 230 nM
target concentration and total probe concentration range 25 nM - 500 nM. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society
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(a)

(b)
Figure 4.6. Original spectra corrected for background (a) and normalized spectra (b) for 460 nM
target concentration and probe range 50 nM - 1200 nM. This figure is reproduced by permission
from [120]. Copyright 2018, American Chemical Society
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(a)

(b)
Figure 4.7. Original spectra corrected for background (a) and normalized spectra (b) for 700 nM
target concentration and total probe concentration range 400 nM – 1500 nM. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society
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According to our signal transduction design, the inflection point of the response profile
should correlate with the target amount. Hence, we took the FAM/TMR ratio values and plotted
them against the total probe concentration. The resulting curves are sigmoidal curves where each
of the curve has characteristic inflection point (Figure 4.18. a and b).

(a)

(b)

Figure 4.8. Transition curves for target/probe binding. (a) The curves result in a characteristic
sigmoid shape for a range of target concentrations. The inflection point between initial plateau
and slope indicates the target concentration. The data included in this Figure were acquired
using three different spectrofluorimeters in three different labs. No data normalization was
performed. The figure illustrates the power of the quantitation approach: despite a noticeable
variability in signal magnitude resulting from day-to-day and/or instrument-to-instrument
variations, the position of the inflection point on a response profile correlates with target’s
quantity in sample. (b) The same data are presented in a normalized format. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society

Further, beyond the visual conﬁrmation of correlation between the position of response
proﬁle and target amount, we looked into a more formal way of establishing the inﬂection point
and, consequently, target quantity. While the data can be ﬁt with sigmoidal ﬁts, the ﬁt does not
yield the inﬂection point and, consequently, the quantitation information. Therefore, we have to
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establish a procedure for deriving the inﬂection point. In order do it, we evaluated two procedures
based on the inﬂection point’s physical meaning. The methods are explained below:
4.1.1. Method 1
In method 1, we determined the inflection point quantitatively based on a curve fitting method.
After finding the FAM/TMR ratios, we plotted the values against the total probe concentration and
then fitted the scatters in a Hill equation. This generated a curve along with equation that proves
the values of starting point, midpoint, end point and slope.
𝑦 = 𝑆𝑇𝐴𝑅𝑇 + (𝐸𝑁𝐷 − 𝑆𝑇𝐴𝑅𝑇) ∗
Start
±
Standard error

target conc.

𝑥𝑛
𝑥 𝑛 +𝑘 𝑛

Value

Standard
error

Start

3.50306

0.04707

End

2.38611

0.07214

k

1.5876E-7

4.56922E-9

n

11.62958

3.47332

PROBE CONCENTRATION

Figure 4.9. Fitting the FAM/TMR ratio against total probe concentration with Hill equation. The
fit generates value for start plateau, end plateau, k (transition midpoint) and n (slope). This figure
is reproduced by permission from [120]. Copyright 2018, American Chemical Society

But none of these values provide the inflection point. However, if we take the standard
deviation of the start plateau, the intersection of the standard deviation and the hill plot curve can
give us an exact value of inflection point that can be correlated with the corresponding target
concentration (Figure 4.9.). We calculated this inflection point from three replicates prepared for
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each sample set. After calculating three inflection points for each sample set, we then calculated
the average of inflection point along with standard deviation.

4.1.2. Method 2
In Method 2, the ratios are plotted against total probe concentration. Then initial plateau and
transition slope are fitted with linear regressions. The intersection of these two extrapolating lines
can also be considered as the inflection point, which is correlated with the target concentration
(Figure 4.10.). Like method 1, we then calculated this inflection point from three replicates
prepared for each sample set and determined the average of inflection point along with standard
deviation.

target conc.

PROBE CONCENTRATION
Figure 4.10. Plotting the FAM/TMR ratio against total probe concentration. The intersection
from extrapolating lines of starting plateau and transition slope can determine the target
concentration. This figure is reproduced by permission from [120]. Copyright 2018, American
Chemical Society

We then compared the data collected from both methods. As a result, both approaches
yielded accurate values for target quantities over a concentration range exceeding 2 orders of
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magnitude regardless of which method was used to discern the inﬂection point (bottom table in
Figure 4.11.). We observed the highest deviations from the expected values for the lowest (10 nM)
target concentration. We speculate that the need to measure very low signals (close to limit of
regular spectroﬂuorimeter) is the reason for inaccuracies at this level.

Figure 4.11. Two methods for discerning value of inﬂection point yield similar results. The
results agree well with target contents over a wide concentration range. % RSDs over multiple
measurements of inﬂection point (n = 3−8) are ≤15%. Colors in table in panel is synchronized
with curves showed in the sigmoidal curve in Figure 4.8. This figure is reproduced by permission
from [120]. Copyright 2018, American Chemical Society

The conclusion is based on the assumption that if the inaccuracy originates from
concentrations of probes and/or target being too low to ensure 1:2 target-probe hybrid formation,
the inﬂection point would be shifted toward higher total probe concentrations; however, the
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situation is completely the opposite: the inﬂection point is shifted toward a lower concentration.
Therefore, at this moment, our ability to evaluate small target concentrations (<20 nM) is limited
by FRET-based signal transduction platform. The actual limitations of the approach with respect
to equilibrium parameters are currently under investigation.
Overall, it is worth mentioning that while both methods for establishing an inﬂection point
provide similar results, both of them have limitations: Method 1 requires collecting data to cover
the whole sigmoid curve and performing a sigmoid ﬁt (to determine the value of initial plateau and
its standard error via a ﬁtting procedure) that may be deemed impractical in certain situations,
while Method 2 involves subjective choice of plateau vs slope points.
4.2 Specificity of the approach
To be practically sound, this response profile based approach should be specific towards
target oligonucleotides. Hence, in order establish specificity, we evaluated the response of this
mechanism in some control conditions. These are explained below.
4.2.1 Control Experiment in Absence and Presence of Target
Our first control experiment was carried out in the absence and presence of target
oligonucleotide. Here we prepared two set of samples at a certain target concentration. One set of
samples had a fixed target concentration (i.e. 10 nM, 20 nM and 230 nM), while the other set of
samples did not have any target. Probe concentration in both sets were equivalent and designed to
overlap the target concentration (sample preparation pattern is similar with Table no. 3.2). All the
samples from both sets went through a similar sample preparation method and measurement
protocol. As the probe concentration kept increasing, the emission intensity of the spectra kept
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increasing (Figure 4.12.). After plotting the ratio of FAM/TMR with respect to total probe
concentration, we observe that there was no change in FRET signal in the samples with no target.
Hence, FRET did not take place in those samples. However, samples with a target showed the
changes in FRET value (Figure 4.13.).

Figure 4.12. Emission spectra for two set of samples in presence and absence of target. The top
two (a) and (b) with 230 nM target and the bottom two (c) and (d) without target. This figure is
reproduced by permission from [120]. Copyright 2018, American Chemical Society
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The control experiment was established for total probe concentrations covering target range
for 10 nM, 20 nM and 230 nM and none of them showed any changes in FRET signal (FAM/TMR
ratio) in absence of target, while samples with a target showed change in FRET signal (Figure
4.13. c)

(a)

(b)

(c)
Figure 4.13. Control experiment in presence, absence of target and also in presence of random
DNA (a) and (b) transition at the target concentration of 10 nM and 20 nM: with target present
(black squares), with probes only (blue triangles), and with random DNA (no target) at the
concentration of 10 nM and 20 nM (red circles). (c) Transition at the target concentration of 230
nM: with target present at 230 nM (black squares) and with probes only (red circles). This figure
is reproduced by permission from [120]. Copyright 2018, American Chemical Society
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4.2.2 Control experiment in presence of Random DNA
Our second control experiment was carried out in the presence and in the absence of
random DNA. Here, we prepared three sets of samples for a certain target concentration. One set
had a fixed target concentration (i.e., 10 nM and 20 nM), the second set did not have any target,
while the last set had a random DNA instead of a target, which was not complementary with either
probe. Probe concentration in both sets were equivalent and designed to overlap the target
concentration.

All sets of samples went through similar sample preparation methods and

measurement protocol. We then processed the data to compare changes in FRET signal among
these three set of samples. As expected, there was no change in the FAM/TMR ratio with respect
to the total probe concentration in the samples with no target samples, while samples with the
target showed change in the FAM/TMR ratio (Figure 4.13. (a) and (b)). However, samples with
random DNA didn’t show any change in FRET signal as well. In conclusion, it can be said that
the binding model is very specific in terms of showing response profile.
4.3 Quantitative analysis of target in presence of excess random DNA
4.3.1 Introduction
The response profile based approach for quantifying nucleic acid was developed based on
high binding specificity as both probes are complementary with the target sequence along with an
overlapping binding region. However, it was necessary to evaluate the quantitation specificity of
this mechanism in the presence of random DNA for practical application: i.e., in vitro or in vivo
analysis of nucleic acid. In both cases, along with the target nucleic acid, there might be other
nucleic acids that can interact with the probes, which may affect the specificity of the target-probe
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binding. Hence, we tried to evaluate whether our sensing system was capable of quantifying the
target in the presence of excess amount of random DNA.
4.3.2 Materials and Method
To evaluate the specificity of this mechanism, we carried out several sets of experiments by
preparing samples with diﬀerent amounts (equimolar, two times, 3.8 times of target template
concentration) of a random DNA that does not bind probes. The sequence of random DNA is
shown in Table 3.1.

Figure 4.14. Target can be reliably quantitated in the presence of excessive amounts of random
DNA. Red points/curves, target only, no random DNA; black points/curves, target + equimolar
amounts of random DNA; blue points/curves, target + 2× amounts of random DNA; green
points/curve, target + 3.8× amounts of random DNA. Solid symbols/solid lines, target at 20 nM;
empty symbols/dashed lines, target at 40 nM. * “np” means “not performed.” Method 2 was used
to determine target concentration. Colors in table are synchronized with colors of data
points/curves [116]. Copyright 2018, American Chemical Society
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Samples from all of the sets had a constant target concentration (i.e., 20 nM or 40 nM) along
with a certain range of total probe concentration. Samples from all of the sets went through a
similar sample preparation process. After sample preparation, emission spectra of all the samples
were evaluated.
4.3.3 Result and Discussion
After analyzing the data from the specificity experiments, it has been seen that the
quantitative value of the target concentration from the response profile wasn’t significantly
affected by the presence of equimolar or even higher concentrations of random DNA than the
target (Figure 4.14.). Hence, the results indicate that the approach yields accurate target
quantiﬁcation in the presence of exceeding amounts of a random background.

CHAPTER 5
OPTIMIZING BINDING MODEL
5.1 Introduction
Chapter 3 mentioned that the binding cooperativity can be characterized by c, where the
parameter c= 𝐾𝑇→𝑇𝑃1 / 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 , c < 1 corresponds to negative cooperativity and c > 1 to positive
cooperativity.
According to our theoretical explanation of the binding mechanism, the position of response
profile as a function of target concentration is based on assumption of high negative cooperativity.
Therefore, we need a higher value of 𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2 than 𝐾𝑇→𝑇𝑃1 to produce target amount dependent
response profile.
In order to evaluate our binding model, we need to establish dissociation constants from the
sequential binding events between target and probes. Dissociation constants for target-probe (T/P)
binding events were determined from ∆Gº values that are calculated by using Oligo Analyzer Tool
(IDT DNA). The binding events are shown below:
𝐾𝑇→𝑇𝑃1

𝑇 + 𝑃1 ↔

𝐾𝑇→𝑇𝑃2

𝑇 + 𝑃2 ↔

𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2

𝑇𝑃1 + 𝑃2 ↔

𝐾𝑇𝑃2 →𝑇𝑃1 𝑃2

𝑇𝑃2 + 𝑃1 ↔

𝑇𝑃1 𝑃2

.….

Eq (1)

𝑇𝑃1 𝑃2

…..

Eq (2)

For first binding (T+P1 or T+P2) event, the binding over total probe length was evaluated to get
the ∆Gº value. For second binding event, the half of overlap region was considered for each event.
The equation for determining the dissociation constant is

-∆Gº/RT

K =e
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……

Eq (3)

In this chapter, our ultimate goal is to evaluate and optimize the binding system based on ‘c’ value
and to evaluate the optimizing effect on determining the target amount.
5.2 Experimental procedure
From our current system (Figure 5.1.), we determined the ∆Gº values and dissociation
constants using eq’n 3. The values are shown in table 5.1. After that, we determined ‘c’ values to
evaluate their cooperativity. The values are shown in Eq 4 and 5.
C=

𝐾𝑇→𝑇𝑃1
𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2

C= 𝐾

𝐾𝑇→𝑇𝑃2

𝑇𝑃2 →𝑇𝑃1 𝑃2

= 22.4
= 7 × 10−9

…..
…..

Eq (4)
Eq (5)

Here we observed that, if the binding event starts with probe 1, followed by probe 2, the ‘c’
value is 22.4, which means these sequential bindings don’t have negative cooperativity effect,
however, if we start our binding event with probe 2, followed by probe 1, the ‘c’ value is 7 × 10−9 .

3’ TC TGT AGG TCT GGT CCC GTG 5’
5’TAT TTC TTA TTC ATA TTC AGG AAG ACA TCC AGA CCA GGG CAC 3’
3 ATA AAG AAT AAG TAT AAG TCC TTC TGT A 5’
Figure 5.1. Current binding system with target and probes sequences.

As we found our current binding system doesn’t show negative cooperativity in one
pathway(c=22.4), we redesigned the system by making a change in our binding model sequence
for template and probe 1 (TMR).
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3’ TC TGT AGG TCT GGT CCC GTG CG 5’
5’TAT TTC TTA TTC ATA TTC AGG AAG ACA TCC AGA CCA GGG CAC GC3’
3’ATA AAG AAT AAG TAT AAG TCC TTC TGT A 5’
Figure 5.2. Newly designed model with new target and probe 1 sequence. Here CG base was
introduced in 5’ end of probe 1 and complementary GC base was introduced in the 3’ end of
template.

Here, we increased the length of template oligonucleotide and probe 1 (TMR)
oligonucleotide by introducing two bases of GC content in the 3’ end of template and
complimentary CG 5’ end of probe 1 respectively (Figure 5.2.). To evaluate the newly redesigned
𝐾𝑇→𝑇𝑃1
binding model, we determined their
dissociation constant by calculating
𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2
∆G values using Oligo Analyzer Tool (IDT DNA). The values of ∆Gº and corresponding
equilibrium constants from both current and new systems are shown in Table 5.1. After
determining the dissociation constants, we then calculated the ‘c’ values from the sequential
binding events.
𝐾𝑇→𝑇𝑃1
𝐾𝑇𝑃1 →𝑇𝑃1 𝑃2
𝐾𝑇→𝑇𝑃2
𝐾𝑇𝑃2 →𝑇𝑃1 𝑃2

= 1.9 × 10−4
= 8 × 10−4

Eq(6)
Eq(7)

Here we can see that, the ‘c’ values are less than ‘1’ considering both pathways (Eq 6 and 7).
Therefore, theoretically, this newly designed system is much more optimized and symmetric than
the current system.
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Table 5.1. Comparison ∆Gº and their corresponding ‘K’ values from sequential binding event
between current and new system

current
system

new system

Binding
event
T→TP1
TP1→TP1P2
T→TP2
TP2→TP1P2
T→TP1
TP1→TP1P2
T→TP2
TP2→TP1P2

∆G º
(kcal/mole
-38.25
-33.74
-44.86
-28.73
-45.17
-40.65
-44.86
-40.09

R value
1.99x10-03
1.99x10-03
1.99x10-03
1.99x10-03
1.99x10-03
1.99x10-03
1.99x10-03
1.99x10-03

T in K

‘K’ value

298
298
298
298
298
298
298
298

8.88x10-29
3.97x10-30
1.26x10-33
3.972x10-30
7.47x10-34
1.54x10-30
1.26x10-33
3.97x10-30

To observe the impact of new binding system on the response profile, we carried out
experiments to evaluate this new binding model. We evaluated this new system for target
concentration at 20 nM and 40 nM where each set had corresponding range of probe
concentrations. For both sets, we also carried out the same experiment with our current system as
our control. All the samples went through same sample preparation procedure and measurement
protocol.
5.3 Results
After plotting the data, obtained from the experiment, we assessed both systems with
accuracy for determination of inflection point in order to get the quantitative information of target.
We observed from the set of 20 nM target that the target concentration from the corresponding
inflection point was 25±1 nM in case of new binding system, whereas in old binding system, the
target concentration was 22±1 nM.
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Current

Figure 5.3. Comparing the response profile between the current and new binding system at 20
nM and 40 nM target concentration. The new binding system has higher signal to background
ratio compare to the older system.

For 40 nM target, the old system gave 39±1 nM and the new one gave 41±2 nM and 49±1 nM in
method 1 and method 2 respectively. Also, from the graph (Figure 5.3.) we noticed that S/B ratio
for new system in general are higher than for old system.
So, from this experiment, it can be said that in terms of quantitation, the newly designed
method is not strong enough. Our next step would be to continue investigating the how binding
properties of system affect the quantitative results.

CHAPTER 6
CONCLUSION AND FUTURE DIRECTIONS

In conclusion, we developed a new approach for quantitative analysis of oligonucleotide
targets based on the position of the response proﬁle. The capability has enabled quantitative
analysis of nucleic acid via a deliberate incorporation of a negative cooperativity interference into
a target-probe binding model. We demonstrated that the approach allows direct separation-less
assessment of oligonucleotide target amounts over a concentration range of 10-8 to 10-6 M. It is
important that the methodology does not require a target standard and/or a calibration. Importantly,
the approach has a broader utility for quantitative assessment of other biomolecules as the major
design principles are applicable to any target that can bind probes capable of forming a negative
cooperativity pair. The sensitivity of the approach is limited by the target-probe binding aﬃnities
and by the availability of the signal transduction platforms capable of discerning 1:2 target-probe
hybrids. Overall, considering the simplicity along with availability of various signal transduction
mechanisms for nucleic acids [127], we expect the approach to integrate into platforms developed
for the point-of-care and limited resource setting.
Our future research will be focused on extending the quantitation approach to analysis of other
biomolecules such as antibodies. In the case of antibody, we can impose negative cooperativity by
designing two antigens, each attached with a sub-antigen, where the binding affinity of sub-antigen
with target antibody will be lower than the antigen. This antigen along with sub antigen will act a
probe which will decrease sequential binding affinity of the second probe due to the presence of
sub antigen group. Thus, we can impose negative cooperativity in the binding mechanism of
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antigen and antibody. After a certain point, as we will keep increasing the probe concentration,
they will start forming the 1:2 target-probe hybrid (Figure 6.1.). And they can move towards signal
transduction pathway to observe this 1:2 target probe hybrid in order to determine the target
amount from a response profile.

Figure 6.1. Imposing negative cooperativity for quantifying antibody. Here, antibody will be the
target and antigen along with a sub-antigen will act as a probe. Initially they will form 1:1 target
probe binding, later, as with the increase of probe concentration, they will form 1:2 target-probe
hybrid.
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